Gabather poised to complete phase I with GT-002

Gabather poised to complete phase I with GT-002

14 September, 2021As described in their Q2 report, despite the pandemic, Swedish biotech Gabather have taken key steps in the clinical development of its lead candidate GT-002 this year. Since the reporting period, the company has announced submitting an application for initiating a target engagement study with GT-002 in Portugal. If approved, this study will be … Continue reading Gabather poised to complete phase I with GT-002